{
    "info": {
        "nct_id": "NCT04370587",
        "official_title": "A Phase 1/2a, Open-Label, Dose Escalation and Expansion Study of the Safety and Tolerability of T3011 Administered Via Intratumoral Injection as a Single Agent and in Combination With Intravenous Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors",
        "inclusion_criteria": "1. Age 18 years or older.\n2. Disease progression after standard of care (SOC) therapy or in the opinion of\n3. The Investigator unlikely to benefit from SOC therapy. Inclusion Diagnosis Phase 1 - Histologically or pathologically confirmed locally recurrent or metastatic advanced malignancy.\n\n   Phase 2a Part 1 i. Arm A - locally recurrent or metastatic melanoma. Participants must have received no more than 3 prior regimens for advanced or metastatic disease.\n\n   ii. Arm B - locally recurrent or metastatic HNSCC. It must also meet the following criteria: 1) Disease progression to platinum-containing chemotherapy; 2) Failure to anti-PD-1/PDL1 blockade after receiving at least 2 doses alone or in combination.\n\n   iii. Arm C - Sarcoma. Participants must have received no more than three lines of prior anti-cancer therapies.\n\n   iv. Arm D - locally recurrent or metastatic cSCC. Participants must have received no more than 3 prior regimens for advanced or metastatic disease.\n\n   Phase 2a Part 2 i.v. Arm E - Histologically or pathologically confirmed NSCLC that is advanced or recurrent, without EGFR mutation or ALK rearrangement. Participants must have received at least one line but no more than three lines of prior anti-cancer therapies.\n4. Measurable disease per RECIST version 1.1.\n5. Must have at least 1 tumor lesion that is accessible for IT injection of T3011 in the opinion of the investigator.\n6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n7. Life expectancy > 12 weeks.\n8. Demonstrate adequate organ function as defined by acceptable laboratory testing results.\n9. Women of child-bearing potential (WCBP) and men must agree to use adequate contraception prior to study entry, while on study treatment, and for six months after receiving last dose of T3011. WCBP must have a negative serum pregnancy test prior to W1D1.\n10. Last dose of previous anticancer therapy ≥ 21 days, radiotherapy > 21 days, or surgical intervention > 21 days prior to the first dose of T3011.\n11. Recovered from all prior anticancer therapy toxicities.\n12. Willingness to provide fresh tumor biopsy specimens as specified in the Schedule of Assessments.\n13. Capable of understanding and complying with protocol requirements.\n14. Signed and dated institutional review board/independent ethics committee-approved informed consent form before any protocol-directed screening procedures are performed.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Have only uninjectable tumors..\n2. Patients with injectable tumors impinging upon major airways or blood vessels.\n3. HNSCC only: Prior re-irradiation field containing carotid artery.\n4. Greater than 3 distant metastatic lymph node regions and/or metastatic lesions or the largest distant metastases with a diameter of more than 3 cm (non-sarcoma)/5 cm (sarcoma) unless the lesion is to be injected.\n5. Prior treatment with another OV (including T-VEC), tumor vaccines, cellular therapy or gene therapy.\n6. Prior intolerance to anti-PD-(L)1 monoclonal antibody or history of immunotherapy related non-infectious pneumonitis/interstitial lung disease.\n7. Prior treatment with anti-PD-(L)1 monoclonal antibody in combination with IL-12.\n8. Requires continued concurrent therapy with any drug active against HSV.\n9. Live vaccines, attenuated vaccines within 4 weeks prior to initiation of study treatment (participants vaccinated with inactivated vaccines can be enrolled.\n10. Primary or acquired immunodeficient states.\n11. Pregnant or lactating.\n12. Prior organ transplantation.\n13. Active hepatitis B virus, hepatitis C virus, and HIV infection or a positive serological test at Screening within 14 days of dosing with T3011.\n14. Active autoimmune disease or medical conditions requiring chronic steroid or immunosuppressive therapy within 4 weeks prior to first administration of study treatment.\n15. History of or current central nervous system metastases.\n16. History of seizure disorders within 6 months of Screening.\n17. Active oral or skin herpes lesion at Screening.\n18. Active interstitial lung disease (ILD)/pneumonitis or a history of ILD/pneumonitis requiring treatment with systemic steroids.\n19. Congestive heart failure, active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina, or clinically significant cardiac arrhythmias.\n20. History of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody.\n\n18. Active infection with SARS-CoV-2 virus. 21. Participants with moderate to large amount of pleural effusion, ascites or pericardial effusion who need drug or medical intervention.\n\n22. Other systemic conditions or organ abnormalities that, in the opinion of the investigator, may interfere with the conduct and/or interpretation of the current study.",
        "miscellaneous_criteria": "Key"
    },
    "inclusion_lines": [
        {
            "line": "1. Age 18 years or older.",
            "criterions": [
                {
                    "exact_snippets": "Age 18 years or older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Disease progression after standard of care (SOC) therapy or in the opinion of",
            "criterions": [
                {
                    "exact_snippets": "Disease progression after standard of care (SOC) therapy",
                    "criterion": "disease progression after standard of care therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. The Investigator unlikely to benefit from SOC therapy. Inclusion Diagnosis Phase 1 - Histologically or pathologically confirmed locally recurrent or metastatic advanced malignancy.",
            "criterions": [
                {
                    "exact_snippets": "Investigator unlikely to benefit from SOC therapy",
                    "criterion": "likelihood to benefit from standard of care (SOC) therapy",
                    "requirements": [
                        {
                            "requirement_type": "likelihood to benefit",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Histologically or pathologically confirmed locally recurrent or metastatic advanced malignancy",
                    "criterion": "malignancy diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "pathologically"
                            ]
                        },
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "locally recurrent",
                                "metastatic",
                                "advanced"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Phase 2a Part 1 i. Arm A - locally recurrent or metastatic melanoma. Participants must have received no more than 3 prior regimens for advanced or metastatic disease.",
            "criterions": [
                {
                    "exact_snippets": "locally recurrent or metastatic melanoma",
                    "criterion": "melanoma",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "locally recurrent",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "no more than 3 prior regimens for advanced or metastatic disease",
                    "criterion": "number of prior regimens for advanced or metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "regimens"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "ii. Arm B - locally recurrent or metastatic HNSCC. It must also meet the following criteria: 1) Disease progression to platinum-containing chemotherapy; 2) Failure to anti-PD-1/PDL1 blockade after receiving at least 2 doses alone or in combination.",
            "criterions": [
                {
                    "exact_snippets": "locally recurrent or metastatic HNSCC",
                    "criterion": "head and neck squamous cell carcinoma (HNSCC)",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "locally recurrent",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Disease progression to platinum-containing chemotherapy",
                    "criterion": "disease progression after platinum-containing chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "progression after treatment",
                            "expected_value": "platinum-containing chemotherapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "Failure to anti-PD-1/PDL1 blockade after receiving at least 2 doses alone or in combination",
                    "criterion": "response to anti-PD-1/PDL1 blockade",
                    "requirements": [
                        {
                            "requirement_type": "treatment failure",
                            "expected_value": "anti-PD-1/PDL1 blockade"
                        },
                        {
                            "requirement_type": "minimum number of doses",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "doses"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "iv. Arm D - locally recurrent or metastatic cSCC. Participants must have received no more than 3 prior regimens for advanced or metastatic disease.",
            "criterions": [
                {
                    "exact_snippets": "Arm D - locally recurrent or metastatic cSCC",
                    "criterion": "cSCC disease status",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "locally recurrent",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants must have received no more than 3 prior regimens for advanced or metastatic disease",
                    "criterion": "number of prior regimens for advanced or metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "maximum number",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "regimens"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "iii. Arm C - Sarcoma. Participants must have received no more than three lines of prior anti-cancer therapies.",
            "criterions": [
                {
                    "exact_snippets": "Participants must have received no more than three lines of prior anti-cancer therapies.",
                    "criterion": "number of prior anti-cancer therapies",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Measurable disease per RECIST version 1.1.",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease per RECIST version 1.1.",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST version 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Must have at least 1 tumor lesion that is accessible for IT injection of T3011 in the opinion of the investigator.",
            "criterions": [
                {
                    "exact_snippets": "at least 1 tumor lesion",
                    "criterion": "tumor lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "tumor lesion that is accessible for IT injection of T3011",
                    "criterion": "tumor lesion accessibility for IT injection of T3011",
                    "requirements": [
                        {
                            "requirement_type": "accessibility for IT injection of T3011",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the investigator",
                    "criterion": "investigator opinion on accessibility",
                    "requirements": [
                        {
                            "requirement_type": "investigator opinion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0-1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Phase 2a Part 2 i.v. Arm E - Histologically or pathologically confirmed NSCLC that is advanced or recurrent, without EGFR mutation or ALK rearrangement. Participants must have received at least one line but no more than three lines of prior anti-cancer therapies.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or pathologically confirmed NSCLC",
                    "criterion": "NSCLC diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "pathologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "advanced or recurrent",
                    "criterion": "NSCLC disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "advanced",
                                "recurrent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "without EGFR mutation or ALK rearrangement",
                    "criterion": "EGFR mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "without EGFR mutation or ALK rearrangement",
                    "criterion": "ALK rearrangement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants must have received at least one line but no more than three lines of prior anti-cancer therapies",
                    "criterion": "prior lines of anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of lines",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "lines"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "lines"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Life expectancy > 12 weeks.",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy > 12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Demonstrate adequate organ function as defined by acceptable laboratory testing results.",
            "criterions": [
                {
                    "exact_snippets": "Demonstrate adequate organ function as defined by acceptable laboratory testing results.",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "laboratory testing results",
                            "expected_value": "acceptable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Women of child-bearing potential (WCBP) and men must agree to use adequate contraception prior to study entry, while on study treatment, and for six months after receiving last dose of T3011. WCBP must have a negative serum pregnancy test prior to W1D1.",
            "criterions": [
                {
                    "exact_snippets": "Women of child-bearing potential (WCBP) and men must agree to use adequate contraception prior to study entry, while on study treatment, and for six months after receiving last dose of T3011.",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "prior to study entry",
                                "while on study treatment",
                                "for six months after receiving last dose of T3011"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "WCBP must have a negative serum pregnancy test prior to W1D1.",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to W1D1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Recovered from all prior anticancer therapy toxicities.",
            "criterions": [
                {
                    "exact_snippets": "Recovered from all prior anticancer therapy toxicities.",
                    "criterion": "prior anticancer therapy toxicities",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Last dose of previous anticancer therapy ≥ 21 days, radiotherapy > 21 days, or surgical intervention > 21 days prior to the first dose of T3011.",
            "criterions": [
                {
                    "exact_snippets": "Last dose of previous anticancer therapy ≥ 21 days ... prior to the first dose of T3011",
                    "criterion": "time since last dose of previous anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "time interval",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "radiotherapy > 21 days ... prior to the first dose of T3011",
                    "criterion": "time since radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time interval",
                            "expected_value": {
                                "operator": ">",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "surgical intervention > 21 days prior to the first dose of T3011",
                    "criterion": "time since surgical intervention",
                    "requirements": [
                        {
                            "requirement_type": "time interval",
                            "expected_value": {
                                "operator": ">",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Willingness to provide fresh tumor biopsy specimens as specified in the Schedule of Assessments.",
            "criterions": [
                {
                    "exact_snippets": "Willingness to provide fresh tumor biopsy specimens",
                    "criterion": "fresh tumor biopsy specimens",
                    "requirements": [
                        {
                            "requirement_type": "willingness to provide",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Capable of understanding and complying with protocol requirements.",
            "criterions": [
                {
                    "exact_snippets": "Capable of understanding and complying with protocol requirements",
                    "criterion": "ability to understand and comply with protocol requirements",
                    "requirements": [
                        {
                            "requirement_type": "capability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Signed and dated institutional review board/independent ethics committee-approved informed consent form before any protocol-directed screening procedures are performed.",
            "criterions": [
                {
                    "exact_snippets": "Signed and dated ... informed consent form",
                    "criterion": "informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dated",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "institutional review board/independent ethics committee-approved",
                    "criterion": "informed consent form approval",
                    "requirements": [
                        {
                            "requirement_type": "approval authority",
                            "expected_value": [
                                "institutional review board",
                                "independent ethics committee"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "before any protocol-directed screening procedures are performed",
                    "criterion": "timing of informed consent",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "before protocol-directed screening procedures"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "22. Other systemic conditions or organ abnormalities that, in the opinion of the investigator, may interfere with the conduct and/or interpretation of the current study.",
            "criterions": [
                {
                    "exact_snippets": "Other systemic conditions or organ abnormalities ... may interfere with the conduct and/or interpretation of the current study",
                    "criterion": "systemic conditions or organ abnormalities",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with study",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "investigator opinion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Prior treatment with anti-PD-(L)1 monoclonal antibody in combination with IL-12.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with anti-PD-(L)1 monoclonal antibody in combination with IL-12",
                    "criterion": "prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "anti-PD-(L)1 monoclonal antibody",
                                "IL-12"
                            ]
                        },
                        {
                            "requirement_type": "combination",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. History of or current central nervous system metastases.",
            "criterions": [
                {
                    "exact_snippets": "History of or current central nervous system metastases.",
                    "criterion": "central nervous system metastases",
                    "requirements": [
                        {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Primary or acquired immunodeficient states.",
            "criterions": [
                {
                    "exact_snippets": "Primary or acquired immunodeficient states.",
                    "criterion": "immunodeficient state",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "primary",
                                "acquired"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. History of seizure disorders within 6 months of Screening.",
            "criterions": [
                {
                    "exact_snippets": "History of seizure disorders within 6 months of Screening.",
                    "criterion": "seizure disorders",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to Screening"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Active oral or skin herpes lesion at Screening.",
            "criterions": [
                {
                    "exact_snippets": "Active oral or skin herpes lesion at Screening",
                    "criterion": "oral herpes lesion",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at Screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "Active oral or skin herpes lesion at Screening",
                    "criterion": "skin herpes lesion",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at Screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Greater than 3 distant metastatic lymph node regions and/or metastatic lesions or the largest distant metastases with a diameter of more than 3 cm (non-sarcoma)/5 cm (sarcoma) unless the lesion is to be injected.",
            "criterions": [
                {
                    "exact_snippets": "Greater than 3 distant metastatic lymph node regions",
                    "criterion": "distant metastatic lymph node regions",
                    "requirements": [
                        {
                            "requirement_type": "count",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "regions"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "metastatic lesions",
                    "criterion": "metastatic lesions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the largest distant metastases with a diameter of more than 3 cm (non-sarcoma)",
                    "criterion": "largest distant metastasis diameter (non-sarcoma)",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "cm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "the largest distant metastases with a diameter of more than ... 5 cm (sarcoma)",
                    "criterion": "largest distant metastasis diameter (sarcoma)",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "cm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless the lesion is to be injected",
                    "criterion": "lesion to be injected",
                    "requirements": [
                        {
                            "requirement_type": "planned injection",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Live vaccines, attenuated vaccines within 4 weeks prior to initiation of study treatment (participants vaccinated with inactivated vaccines can be enrolled.",
            "criterions": [
                {
                    "exact_snippets": "Live vaccines, attenuated vaccines within 4 weeks prior to initiation of study treatment",
                    "criterion": "receipt of live or attenuated vaccines",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "participants vaccinated with inactivated vaccines can be enrolled",
                    "criterion": "receipt of inactivated vaccines",
                    "requirements": [
                        {
                            "requirement_type": "vaccine type",
                            "expected_value": "inactivated"
                        },
                        {
                            "requirement_type": "enrollment eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Prior treatment with another OV (including T-VEC), tumor vaccines, cellular therapy or gene therapy.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with another OV (including T-VEC)",
                    "criterion": "prior treatment with oncolytic virus (OV)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... tumor vaccines",
                    "criterion": "prior treatment with tumor vaccines",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... cellular therapy",
                    "criterion": "prior treatment with cellular therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... gene therapy",
                    "criterion": "prior treatment with gene therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "19. Congestive heart failure, active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina, or clinically significant cardiac arrhythmias.",
            "criterions": [
                {
                    "exact_snippets": "Congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active coronary artery disease",
                    "criterion": "coronary artery disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "unevaluated new onset angina within 3 months",
                    "criterion": "new onset angina",
                    "requirements": [
                        {
                            "requirement_type": "evaluation_status",
                            "expected_value": "unevaluated"
                        },
                        {
                            "requirement_type": "onset_time",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant cardiac arrhythmias",
                    "criterion": "cardiac arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "clinical_significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Have only uninjectable tumors..",
            "criterions": [
                {
                    "exact_snippets": "Have only uninjectable tumors.",
                    "criterion": "tumor injectability",
                    "requirements": [
                        {
                            "requirement_type": "injectability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Prior organ transplantation.",
            "criterions": [
                {
                    "exact_snippets": "Prior organ transplantation.",
                    "criterion": "organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Active autoimmune disease or medical conditions requiring chronic steroid or immunosuppressive therapy within 4 weeks prior to first administration of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "medical conditions requiring chronic steroid or immunosuppressive therapy within 4 weeks prior to first administration of study treatment",
                    "criterion": "medical conditions requiring chronic steroid or immunosuppressive therapy",
                    "requirements": [
                        {
                            "requirement_type": "requirement for chronic steroid or immunosuppressive therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to first administration of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "20. History of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody.",
            "criterions": [
                {
                    "exact_snippets": "History of allergic reactions attributed to compounds of similar biological composition to HSV-1",
                    "criterion": "allergic reactions to compounds similar to HSV-1",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of allergic reactions attributed to compounds of similar biological composition to ... IL-12",
                    "criterion": "allergic reactions to compounds similar to IL-12",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of allergic reactions attributed to compounds of similar biological composition to ... anti-PD-1 monoclonal antibody",
                    "criterion": "allergic reactions to compounds similar to anti-PD-1 monoclonal antibody",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Active hepatitis B virus, hepatitis C virus, and HIV infection or a positive serological test at Screening within 14 days of dosing with T3011.",
            "criterions": [
                {
                    "exact_snippets": "Active hepatitis B virus",
                    "criterion": "hepatitis B virus infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Active ... hepatitis C virus",
                    "criterion": "hepatitis C virus infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Active ... HIV infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "a positive serological test at Screening within 14 days of dosing with T3011",
                    "criterion": "serological test for hepatitis B virus, hepatitis C virus, and HIV",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 14 days of dosing with T3011"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Requires continued concurrent therapy with any drug active against HSV.",
            "criterions": [
                {
                    "exact_snippets": "Requires continued concurrent therapy with any drug active against HSV.",
                    "criterion": "concurrent therapy with drug active against HSV",
                    "requirements": [
                        {
                            "requirement_type": "continuation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. HNSCC only: Prior re-irradiation field containing carotid artery.",
            "criterions": [
                {
                    "exact_snippets": "HNSCC only",
                    "criterion": "diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": "head and neck squamous cell carcinoma (HNSCC)"
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior re-irradiation field containing carotid artery",
                    "criterion": "prior re-irradiation field",
                    "requirements": [
                        {
                            "requirement_type": "anatomical location",
                            "expected_value": "containing carotid artery"
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. Active interstitial lung disease (ILD)/pneumonitis or a history of ILD/pneumonitis requiring treatment with systemic steroids.",
            "criterions": [
                {
                    "exact_snippets": "Active interstitial lung disease (ILD)/pneumonitis",
                    "criterion": "interstitial lung disease (ILD)/pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ILD/pneumonitis requiring treatment with systemic steroids",
                    "criterion": "interstitial lung disease (ILD)/pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment with systemic steroids",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Prior intolerance to anti-PD-(L)1 monoclonal antibody or history of immunotherapy related non-infectious pneumonitis/interstitial lung disease.",
            "criterions": [
                {
                    "exact_snippets": "Prior intolerance to anti-PD-(L)1 monoclonal antibody",
                    "criterion": "intolerance to anti-PD-(L)1 monoclonal antibody",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of immunotherapy related non-infectious pneumonitis/interstitial lung disease",
                    "criterion": "immunotherapy related non-infectious pneumonitis/interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. Active infection with SARS-CoV-2 virus. 21. Participants with moderate to large amount of pleural effusion, ascites or pericardial effusion who need drug or medical intervention.",
            "criterions": [
                {
                    "exact_snippets": "Active infection with SARS-CoV-2 virus",
                    "criterion": "SARS-CoV-2 infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "moderate to large amount of pleural effusion",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "amount",
                            "expected_value": [
                                "moderate",
                                "large"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "moderate to large amount of ... ascites",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "amount",
                            "expected_value": [
                                "moderate",
                                "large"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "moderate to large amount of ... pericardial effusion",
                    "criterion": "pericardial effusion",
                    "requirements": [
                        {
                            "requirement_type": "amount",
                            "expected_value": [
                                "moderate",
                                "large"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "who need drug or medical intervention",
                    "criterion": "need for drug or medical intervention for pleural effusion, ascites or pericardial effusion",
                    "requirements": [
                        {
                            "requirement_type": "need for intervention",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Patients with injectable tumors impinging upon major airways or blood vessels.",
            "criterions": [
                {
                    "exact_snippets": "injectable tumors impinging upon major airways",
                    "criterion": "injectable tumor impingement on major airways",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "injectable tumors impinging upon ... blood vessels",
                    "criterion": "injectable tumor impingement on blood vessels",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Pregnant or lactating.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key eligibility criteria",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}